Thank you.
And once again, welcome to Addvise Group's Q3 2024 Earnings Call. We will take you through the business update and the group's financial performance, and then we will open up for a Q&A session. Q3 was a stable quarter. Our net sales came in at 404 million SEK, which takes us to a year-on-year growth of 26%. However, we continue to see challenging comparables in pharma and clinical trials following last year's stellar performance. This effect will remain, but on a lower level during Q4, with no effect from Q1 next year and onwards. That led us to isolated negative organic growth of -25% for the quarter. EBITA came in at 88 million SEK, which takes us to a 22% EBITDA margin. To provide more insight into the underlying business, if we exclude pharma and clinical trials, we observed an organic growth of 6% for the first nine months. We had a stable order intake in the quarter, up 17%. Year on year, the quarter saw one of the biggest orders in the Nordics ever, but otherwise no big outliers. EBITDA came in at 74 million SEK versus 71 million, a small increase of 4%, mainly due to normalized depreciation levels in clinical trials. Looking at the cash flow from operations, it was 32 million SEK, mainly affected by growth-related CapEx, investments in production capacity, and growth in our clinical trials business. Cash on hand is approximately 400 million SEK. On the M&A side, we cautiously monitor the net leverage and keep that in mind while looking at new opportunities. Coming into the commercial and operational highlights of Q3, we saw some improvements in business momentum, but from moderate levels during the quarter. Our recently acquired businesses are performing according to or slightly above plan, and the lion's share of them will start to affect organic growth in Q4. But we will still experience some effects from the exceptional performance of the pharma business during Q4 2024. In terms of geography, 45% of our sales in the quarter isolated came from North America, and our second largest market in Europe, excluding Sweden. And the third largest market is South America. Looking at our sales by product category. The top three product categories year to date are medical consumables, followed by lab equipment and then medical devices. As you can see on this pie chart, Pharma is now stabilizing around 7% of our sales year to date. And compare that to last year or the peak levels in pharma. Pharma was about 20 to 25% of sales. We clearly see signs of improvement in the demand for capital goods in the US during the quarter. Our sales have been growing over the last four years. As you can see now, we are about $1.5 billion in sales. And if you look at the quarter in isolation. We came in at 404 million SEK. SEK, an organic drop of 19% due to the elements I just mentioned. We also measure our revenues in own products. Products that we develop and manufacture, and products that we distribute. Q3 year to date, own products came in at 56% of our sales, and that is a level we are satisfied with going forward. Order intake. The quarter recorded a healthy growth of 17%. New orders received amounted to 442 million for the quarter. As I said earlier, there was no single big contributor. However, the Nordics were strong. Uh, and we see improving momentum in the US. Looking at the two segments, healthcare came out strong. But please bear in mind that the lab segment is more tilted toward project-related orders, hence bigger ones, resulting in higher volatility between quarters. All in all, we have a solid order backlog to convert into sales in the coming quarters. Splitting the group into healthcare and lab and looking at healthcare. Our sales came in at 249 million SEK in the quarter, an organic drop of 22%. The lab segment reported sales of $154 million for the quarter. Organic sales came in at -44%, heavily affected by the one-off type of revenue in the European clinical trial last year. Margin wise, healthcare came in at 16%. EBITA margin in the lab segment came in at 25% for the quarter. Isolated. Looking at net sales by geography for the healthcare segment, North America is the key market and will continue to be that for a long time.
Having said that, South America is a very fast-growing market compared to the other markets that are slightly more mature, and our operation in that region is clearly performing according to plan. The lab segment is very well diversified when it comes to sales by geography. The largest market is now Europe, excluding Sweden. I'm now handing over to Johan Irwe to take you through the group's financial performance. Thank you, Staffan, and good afternoon all. I am pleased to be here today and take you through the numbers for the third quarter of 2024. EBITDA in the quarter amounted to 88 million SEK, which corresponds to a margin of 22%. This is lower than the same period last year and is primarily driven by a change in product mix. As Staffan just pointed out, we are. We meet challenging comparable figures from the product segments Pharmaceuticals and equipment for clinical trials, which has brought down profitability compared with last year. On a rolling 12-month basis, we are running at an EBITDA of 416 million, which equals a margin of 26%. Worth mentioning here is that the four acquisitions, which we completed during the back end of last year, are all performing in line with or above our expectations, and are all contributing to group profitability. Looking at our profitability metrics for the quarter, we have seen operating profits at similar levels to those in the third quarter of 2023. EBITDA is down 6% while net income is up 4%. The improved EBITDA in Q3 this year is explained by normalized depreciation levels in 2020. For last year, depreciation expenses were mainly driven by the high activity in our rental business for equipment for clinical trials. Net income is down from 35 million to 12 million SEK, driven by higher interest expenses on loans as well as high currency gains in the comparable quarter of 2023. Moving on to cash flow and capital efficiency. First, as a reminder, when we talk about cash flow from operations, we look at the underlying cash flow generated by our businesses, with deductions for changes in working capital as well as investments in our asset base, including leases and acquisition-related items. In the third quarter. We see a lower working capital build compared to the first half of the year. Investments include $8 million in payments related to leases and $23 million in new fixed asset investments. These fixed asset investments are mainly related to the rental business areas and production capacity increases, both of which are growth-driven. Return on capital employed, which is a KPI we have started to publish this year, was 13% for the rolling 12-month period. We have not communicated a target for this metric, but expect that we will level out around or above current levels of the high 20% plus return figures in 2023. Moving on to the balance sheet. Our financial position remains solid. Our net leverage stands at 3.3 times EBITDA. Pro forma. This is above our long-term target of being below three times EBITDA. The dollar bond issues earlier this year reduced our effective exposure and improved our maturity profile by pushing about a third of our gross debt out by almost a year to April 2027. The SEK bond matures in May of 2026. At the end of the quarter, we had more than 400 million SEK in cash and cash equivalents plus undrawn credit facilities.
So from a liquidity perspective, we feel very comfortable. This was all from me. I will now hand over to Staffan again for some closing remarks.